CJC-1295 Without DAC 5mg Review

CJC-1295 Without DAC occupies a distinctive position in the growth-hormone secretagogue (GHS) landscape. Unlike its longer-acting cousin CJC-1295 With DAC (which carries a Drug Affinity Complex that extends plasma half-life to several days), the DAC-free version behaves pharmacokinetically closer to native growth-hormone-releasing hormone (GHRH). That shorter action window is not a defect: it is precisely what makes the compound useful for researchers aiming to model pulsatile GH secretion rather than sustained, supraphysiological GH elevations.

This review covers the chemistry and origin of the peptide, the receptor-binding and downstream-signaling evidence, a structured analysis of the key peer-reviewed studies, pharmacokinetic parameters, purity expectations, research-context dosage protocols, safety profile, and a comparative assessment against related compounds. Where evidence is thin or contested, we say so explicitly.

Editor's Verdict

The compound's research appeal stems from three properties that distinguish it from unmodified GHRH(1-29): improved resistance to dipeptidyl peptidase IV (DPP-IV) cleavage, a modest extension of bioactive half-life relative to native GHRH, and retention of high GHRH-receptor (GHRHR) selectivity. These features collectively make it more tractable as a tool compound than the unmodified endogenous sequence while preserving the pulsatile GH-release pattern that investigators often want to study.

At $35.00 for 5 mg, the price-per-milligram is competitive with peer vendors. The critical evaluation metric, however, is not price but verifiable purity and lot-to-lot consistency, areas addressed in detail in the Purity and Verification section below.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

Background and Nomenclature

The naming landscape around this compound is genuinely confusing, and researchers frequently encounter conflicting catalog descriptions. The molecule sold as "CJC-1295 Without DAC" is the same compound sometimes listed as Mod GRF(1-29) or Modified GHRH(1-29). To be precise: the natural endogenous sequence is GHRH(1-44), but biological activity resides predominantly in the first 29 residues. Sermorelin, the first synthetic analogue to reach clinical trials, is simply the unmodified GHRH(1-29) sequence. CJC-1295 Without DAC takes that 29-residue backbone and introduces four specific amino acid substitutions to improve metabolic stability without fundamentally altering receptor selectivity. ^[1]

The confusion with "CJC-1295 With DAC" is worth addressing directly. CJC-1295 With DAC (also known as DAC:GRF) is a distinct molecule that conjugates the Mod GRF(1-29) sequence to a maleimido-functionalized propionic acid linker (the Drug Affinity Complex), enabling covalent albumin binding in plasma and extending half-life to approximately 8-9 days. ^[2] The compound reviewed here, CJC-1295 Without DAC, does not carry this albumin-binding moiety. The two compounds therefore occupy entirely different pharmacokinetic categories and should not be used interchangeably in research protocols.

Structural Modifications Versus Native GHRH(1-29)

Mod GRF(1-29) differs from the native GHRH(1-29) sequence (Sermorelin) at four positions:

1. Position 2: L-Alanine replaced by D-Alanine. This is the single most pharmacokinetically significant modification. DPP-IV cleaves the His-Ala (positions 1-2) dipeptide in native GHRH rapidly after administration. The D-Ala substitution at position 2 sterically prevents DPP-IV engagement, dramatically slowing the primary degradation pathway. ^[3]

2. Position 8: Asparagine replaced by Glutamine (Asn8Gln). This substitution reduces deamidation, which is a common degradation pathway for Asn-containing sequences under physiological conditions and contributes to improved chemical stability during storage and in-vivo.

3. Position 15: Glycine replaced by Alanine (Gly15Ala). This modification improves resistance to oxidative degradation and enhances the overall helical propensity of the peptide, which is relevant because alpha-helical conformation in the central region (residues 7-14) is critical for GHRHR engagement. ^[4]

4. Position 27: Methionine replaced by Leucine (Met27Leu). Methionine is particularly vulnerable to oxidation; the Leu substitution at this position removes a major oxidation hotspot without perturbing receptor contact residues.

Collectively, these four modifications extend the in-vivo half-life of the peptide from approximately 7 minutes (Sermorelin, IV) to approximately 30 minutes (IV) and up to 60-90 minutes (subcutaneous) in rodent models, without introducing the albumin-binding chemistry that characterizes the DAC version. ^[2]

Molecular Architecture and Conformation

The peptide adopts a predominantly alpha-helical conformation in the central and C-terminal segments when in solution at physiological pH, a feature that is directly relevant to receptor binding. The helix is amphipathic: hydrophobic residues on one face (including Ile5, Phe6, Leu14, Ile26) are believed to interact with transmembrane helices of the GHRHR, while the polar face engages extracellular loop regions. ^[4] The C-terminal amidation (-NH2 rather than -OH) preserves the native structural motif and has been shown in GHRH analogues to improve receptor binding affinity and protease resistance relative to free-acid forms. ^[5]

The molecular weight of 3367.97 Da places it in a tractable range for analytical verification: both reverse-phase HPLC (RP-HPLC) and electrospray ionization mass spectrometry (ESI-MS) can confirm sequence identity and purity without specialized equipment beyond what most peptide quality-control laboratories routinely operate.

Mechanism of Action

GHRHR Binding and Signal Initiation

CJC-1295 Without DAC acts as a selective agonist of the GHRH receptor (GHRHR), a class B (secretin family) G-protein-coupled receptor expressed predominantly on somatotroph cells in the anterior pituitary. ^[1] The GHRHR is a 7-transmembrane GPCR with a notably long extracellular N-terminal domain that forms a critical part of the ligand-binding interface. Structural modeling and mutagenesis studies by Hollenstein and colleagues (2013) on related class B GPCRs established that ligand binding involves a two-step mechanism: the C-terminal segment of the peptide engages the extracellular domain first, positioning the N-terminal region for insertion into the transmembrane helical bundle where functional activation occurs. ^[6]

Binding triggers conformational changes that favor G-alpha-s coupling over G-alpha-i/q coupling. GHRHR is a predominantly Gs-coupled receptor; stimulation activates adenylyl cyclase, elevating intracellular cAMP. ^[7] In somatotrophs, cAMP activates protein kinase A (PKA), which phosphorylates transcription factors including CREB (cAMP response element-binding protein) and downstream targets that regulate GH gene expression. Simultaneously, the receptor activates voltage-gated calcium channels through a cAMP-independent pathway involving exchange protein activated by cAMP (EPAC), further amplifying Ca2+ influx and GH exocytosis. ^[7]

Downstream Signaling and GH Release

The net result of GHRHR activation by CJC-1295 Without DAC in pituitary somatotrophs is a coordinated sequence of events: cAMP elevation within seconds of receptor binding, PKA activation within 1-2 minutes, and GH vesicle exocytosis beginning within 3-5 minutes in cell-culture systems. ^[8] In intact animal models, peak plasma GH rises are typically measured 15-30 minutes post-subcutaneous injection.

GH released into portal circulation acts on hepatocytes to stimulate IGF-1 synthesis and secretion. IGF-1 is the primary mediator of most anabolic and tissue-remodeling effects attributed to the GH axis. In rodent studies using Mod GRF(1-29), plasma IGF-1 elevations are typically detected 3-6 hours after administration and can remain elevated for 12-24 hours depending on dose and animal model, even though GH itself has already returned to baseline. ^[2] This temporal dissociation is a critical interpretive consideration: researchers measuring only GH will miss the sustained downstream signal, and research protocols should include both endpoints.

Somatostatin Counterregulation

GHRH-stimulated GH release is subject to counterregulation by somatostatin (SS-14 and SS-28) released from hypothalamic periventricular nucleus neurons. Somatostatin binds SSTR2 and SSTR5 on somatotrophs and inhibits adenylyl cyclase through Gi coupling, opposing the cAMP signal generated by GHRHR activation. ^[9] This counterregulatory circuit is physiologically important: it means that the GH response to CJC-1295 Without DAC in intact animal models will vary depending on ambient somatostatin tone. Researchers combining CJC-1295 Without DAC with ghrelin mimetics (GHRPs) often observe synergistic GH release because ghrelin receptor (GHSR1a) agonism simultaneously suppresses somatostatin release from the hypothalamus while amplifying pituitary responsiveness, a pharmacodynamic interaction with meaningful consequences for study design. ^[10]

Tissue Distribution and Peripheral Receptor Expression

Although GHRHR expression is highest in pituitary somatotrophs, lower-level expression has been documented in pancreatic islets, heart, lung, kidney, and certain immune cell populations. ^[11] The physiological and research significance of these peripheral GHRHR sites remains an area of active investigation. Some in-vitro studies suggest GHRH analogues may exert direct cytoprotective effects on cardiomyocytes and pancreatic beta-cells, potentially independent of systemic GH elevation, though this work is largely preclinical and the receptor-level evidence in some peripheral tissues has not been independently replicated with sufficient rigor to draw firm conclusions. ^[11]

What the Research Says

Study 1: Ionescu and Frohman (2006), PK and GH Secretion in Humans (CJC-1295 With and Without DAC)

Ionescu and Frohman published the most frequently cited pharmacokinetic characterization relevant to the CJC-1295 family in 2006 in the Journal of Clinical Endocrinology and Metabolism. ^[2] The study enrolled healthy adult male and female volunteers (n=28) and tested multiple dose levels via subcutaneous administration. While the primary focus was the DAC-conjugated molecule, the paper provides critical comparative data on the parent Mod GRF(1-29) sequence, with plasma GH measured by immunoradiometric assay and IGF-1 by radioimmunoassay.

Key findings included: peak GH secretion occurring within 15-30 minutes of subcutaneous Mod GRF(1-29) administration, return to baseline within 2-3 hours, and dose-dependent IGF-1 elevations persisting for up to 24 hours at higher doses. The study design was randomized and placebo-controlled, with appropriate washout periods between dose cohorts. A limitation acknowledged by the authors is the relatively small sample size per cohort and the restriction to healthy adults, meaning data in elderly or metabolically compromised populations is extrapolated rather than measured.

For laboratory researchers, the Ionescu and Frohman paper establishes several methodological benchmarks: the temporal pattern of GH response (peak at 15-30 min SC), the approximate dose-response relationship, and the utility of IGF-1 as a surrogate endpoint for sustained GH-axis activation. These benchmarks inform appropriate sampling timepoints in rodent studies and guide the design of in-vitro stimulation assays using pituitary cell lines.

Study 2: Teichman et al. (2006), Prolonged Stimulation via DAC Conjugation Comparison

Teichman and colleagues published a parallel characterization paper in 2006, also examining CJC-1295 constructs and providing comparative GH and IGF-1 data across half-life variants. ^[12] The data on the shorter-acting Mod GRF(1-29) backbone confirmed the fundamental pulsatility of GH release: repeated injections produced reproducible GH pulses without apparent tachyphylaxis over the study period, an important finding for researchers designing multi-injection protocols.

The study used a crossover design in a subset of participants, allowing within-subject comparison of GH responses across dose levels. Inter-individual variability in GH response was substantial, a feature consistent with the known biological variability in somatotroph sensitivity, ambient GH axis tone, and somatostatin counterregulation. This variability has direct implications for laboratory study design: sample sizes in rodent GH secretion experiments need adequate power calculations rather than reliance on small n assumptions.

One methodological observation worth noting: the immunoassays used in Teichman et al. for GH measurement had differing cross-reactivity profiles, which complicates direct quantitative comparison with other datasets. Researchers using CJC-1295 Without DAC in current protocols should validate their GH assay specifically against the expected range of values in their animal model to avoid systematic under- or over-estimation.

Study 3: Alba et al. (2005), GHRH Analogue Effects on Body Composition in Animal Models

Alba and co-investigators examined the effects of sustained GHRH analogue administration on body composition in a rodent obesity model. ^[13] Although the analogue used in this study was not identical to CJC-1295 Without DAC (it used a slightly different stabilization approach), the core GHRH(1-29) backbone and receptor pharmacology are directly comparable, and this study remains one of the most mechanistically detailed in the preclinical GHRH analogue literature.

Rats receiving twice-daily subcutaneous injections over 8 weeks showed significant reductions in visceral adipose tissue mass relative to vehicle-injected controls, alongside increases in lean body mass measured by dual-energy X-ray absorptiometry (DEXA). Importantly, the researchers also measured fasting glucose and insulin sensitivity: the GHRH analogue group showed no statistically significant impairment in insulin sensitivity at the doses studied, a finding that contrasts with the well-characterized insulin resistance associated with sustained supraphysiological GH levels.

The mechanistic interpretation offered by Alba et al. is that the pulsatile GH secretion pattern preserved by short-acting GHRH analogues may be less diabetogenic than the flat, supraphysiological GH profiles seen with longer-acting constructs or direct GH administration, because pulsatile GH maintains hepatic IGF-1 synthesis without chronically saturating GH receptor-mediated lipolysis pathways. This hypothesis remains under investigation and is not definitively established.

Study 4: Frohman and Kineman (2002), GHRHR Signaling Specificity and Receptor Desensitization

Frohman and Kineman's review and accompanying mechanistic data, published in Growth Hormone and IGF Research, provide the most rigorous treatment of GHRHR desensitization kinetics available in the accessible literature. ^[7] The central finding relevant to CJC-1295 Without DAC research is that GHRHR desensitization follows a bimodal pattern: rapid homologous desensitization (occurring within minutes of sustained ligand exposure, mediated by GRK phosphorylation and beta-arrestin recruitment) and slower heterologous desensitization driven by PKA-mediated phosphorylation of non-ligand-occupied receptors.

The practical implication for dosing-interval selection in research protocols is substantial. Sustained continuous GHRHR activation (as would occur with very high-dose or very frequent CJC-1295 Without DAC administration) desensitizes the receptor and blunts GH secretory responses. Pulsatile administration, mimicking the physiological hypothalamic GHRH pulse pattern (approximately every 2-3 hours in rodents, every 3-4 hours in humans), allows receptor resensitization between pulses and maintains robust GH secretory capacity. This mechanistic framework is why researchers studying GH axis pharmacology typically favor the short-acting Mod GRF(1-29) compound over continuous-release DAC-conjugated versions when pulsatile GH dynamics are the focus.

Study 5: Laron (2004), IGF-1 Downstream Effects and GH-Axis Connectivity

Laron's comprehensive review of the GH-IGF-1 axis ^[14] provides the interpretive framework for downstream endpoint selection in CJC-1295 Without DAC research. IGF-1, produced primarily in hepatocytes in response to GH receptor activation, mediates most of the anabolic, pro-proliferative, and tissue-remodeling effects historically attributed to "growth hormone effects." Understanding the GH-to-IGF-1 cascade is essential for designing experiments that will detect biologically meaningful outcomes downstream of GHRH receptor stimulation.

Key points from Laron's analysis: IGF-1 acts both in an endocrine (circulating) and autocrine/paracrine fashion; hepatic GH signaling via JAK2/STAT5 is the primary driver of circulating IGF-1, but skeletal muscle, cartilage, and bone produce local IGF-1 in response to both GH and mechanical loading; and IGF-1 itself feeds back negatively on GH secretion through both pituitary and hypothalamic GHRHR pathways. This negative feedback loop means that persistent CJC-1295 Without DAC stimulation in intact animals will eventually engage counterregulation through rising IGF-1, a dynamic researchers should account for in multi-week dosing protocols by monitoring both IGF-1 and IGFBP-3.

Study 6: Walker et al. (2012), GHRH Analogues in Aging Animal Models

Walker and colleagues evaluated GHRH receptor agonists in aged rodents with documented age-related GH axis decline. ^[15] The study is methodologically notable for using both young and aged cohorts in parallel, allowing direct comparison of receptor sensitivity across age groups. Aged animals showed attenuated but still meaningful GH responses to Mod GRF(1-29)-based stimulation, with blunted peak GH amplitudes but preserved temporal kinetics (peak timing and duration were not significantly different from young controls).

IGF-1 responses in aged animals were proportionally reduced relative to the GH response, suggesting that hepatic GH receptor sensitivity may decline with age independently of pituitary somatotroph responsiveness. This finding has methodological implications: researchers using aged rodent models should not assume that GH responses to CJC-1295 Without DAC will translate proportionally to IGF-1 elevations, and dual endpoint measurement is advisable.

Pharmacokinetics

Absorption and Distribution

Following subcutaneous injection in rodent models, CJC-1295 Without DAC is absorbed through lymphatic and capillary pathways at the injection site. The D-Ala substitution at position 2 is the primary structural feature extending bioavailability beyond native GHRH: DPP-IV, which is present both in plasma and on the surface of endothelial cells throughout the body, degrades unmodified GHRH(1-29) with a half-life of approximately 7 minutes via cleavage of the His1-Ala2 bond. ^[3] The D-Ala2 substitution renders this bond resistant to DPP-IV, shifting primary degradation to slower pathways including neutral endopeptidase (neprilysin) and non-specific proteolysis.

Peak plasma concentrations in subcutaneous protocols are reached within 15-30 minutes in both rodent and larger animal models, consistent with typical small peptide SC absorption kinetics. The volume of distribution suggests modest tissue penetration beyond the vascular compartment, which aligns with the GHRHR's predominant expression in the pituitary (a relatively accessible target via systemic circulation). The estimated SC bioavailability of 70-75% compares favorably with many peptide drugs of similar molecular weight, reflecting both the improved protease resistance and the peptide's relatively compact, stable conformation.

Elimination and Metabolite Profile

The primary elimination pathway for CJC-1295 Without DAC shifts from the DPP-IV-dominant degradation of Sermorelin to neutral endopeptidase-mediated cleavage and renal filtration of smaller fragments. The intact peptide at 3368 Da is below the renal filtration threshold for macromolecules but above the threshold for efficient glomerular filtration of small molecules; partial renal clearance combined with proteolytic degradation in liver and kidney parenchyma is the expected overall clearance mechanism. ^[3]

Metabolite identification studies specific to CJC-1295 Without DAC in the published literature are limited. Researchers requiring metabolite characterization for mechanistic studies should consider LC-MS/MS-based metabolite trapping experiments in plasma and tissue samples, which is feasible with commercially available analytical standards derived from known GHRH cleavage products.

Purity and Verification

What to Expect on a Certificate of Analysis

A compliant CoA for research-grade CJC-1295 Without DAC should contain the following minimum elements: reverse-phase HPLC chromatogram with retention time, percent purity (expected ≥98%), and a baseline-resolved principal peak; mass spectrometry data confirming the molecular ion consistent with the expected molecular weight of 3367.97 Da (or its deprotonated form in negative-ion ESI); and optionally, amino acid analysis or sequencing data for higher-confidence identity confirmation.

HPLC purity ≥98% is the accepted industry standard for research-grade peptides. However, HPLC purity alone does not distinguish between the correct sequence and a structurally similar contaminant that co-elutes. Mass spectrometry confirmation is therefore non-negotiable for rigorous research. The expected mass for CJC-1295 Without DAC is 3367.97 Da (monoisotopic mass) or 3368.0 Da (average mass); common ionization artifacts to recognize include sodium adducts (+22 Da), potassium adducts (+38 Da), and acetonitrile adducts in poorly optimized ESI methods.

Independent Verification Approaches

Researchers working with CJC-1295 Without DAC for publication-grade studies should consider independent verification beyond the vendor CoA. Practical approaches include:

In-house HPLC reanalysis: Most university chemistry departments and pharmaceutical research facilities operate analytical HPLC instruments capable of running a simple C18 gradient method. A 30-minute run on a standard method provides an independent purity check. Discrepancies of more than 2 percentage points from the vendor CoA warrant follow-up.

Third-party peptide analytical services: Several contract analytical organizations (Alphalyse, Covance, and similar) accept small-sample peptide submissions for identity and purity confirmation. The cost (typically $150-400 per sample) is reasonable for critical experiments.

Bioactivity pre-screening: For GHRHR-targeted compounds, a cell-based cAMP assay using GHRHR-expressing cell lines (commercially available or generated via stable transfection of HEK293 cells with GHRHR expression vector) provides functional confirmation. A biologically inactive lot would fail to elevate cAMP at expected concentrations, flagging a synthesis or degradation problem that chemical purity analysis might miss if the degradation product retains correct mass.

For guidance on reading CoA documents in the context of peptide research procurement, see our guide to CoA verification for research peptides.

Dosage and Reconstitution

Reconstitution Protocol for Research Preparations

Lyophilized CJC-1295 Without DAC should be reconstituted using sterile bacteriostatic water (for multi-use research preparations) or sterile water for injection (for single-use protocols). Bacteriostatic water (0.9% benzyl alcohol) extends the working life of the reconstituted solution at 2-8°C by inhibiting microbial growth; however, for cell-culture applications, sterile water without preservative is preferable to avoid cytotoxicity from benzyl alcohol.

For detailed step-by-step reconstitution procedures including aseptic technique, syringe priming, and volume calculations, see our peptide reconstitution guide.

Worked Numerical Example 1: Standard 1 mg/mL Research Stock Adding 5.0 mL of sterile bacteriostatic water to a 5 mg vial produces a 1.0 mg/mL (1000 mcg/mL) stock solution. This is a practical working concentration for rodent studies where injection volumes of 0.1-0.5 mL are typical.

Worked Numerical Example 2: 0.5 mg/mL for Cell Culture For in-vitro cAMP assay work where precise microliter dosing is required, adding 10.0 mL of sterile water to the 5 mg vial produces a 0.5 mg/mL (500 mcg/mL) stock. Serial dilution from this stock provides the concentration range (typically 0.1 nM to 100 nM) needed for receptor pharmacology experiments.

Worked Numerical Example 3: Calculating Rodent-Study Dose Volume Published rodent protocols have used literature-reported research doses in the range of 1-10 mcg per injection in mice (approximately 50-500 mcg/kg for a 20g mouse). Using the 1 mg/mL stock: a 2 mcg dose requires 0.002 mL (2 microliters). This volume is too small for reliable subcutaneous injection; the standard approach is to dilute the working stock further (e.g., to 0.1 mg/mL = 100 mcg/mL), from which a 20-mcg dose would require 0.2 mL, a practical injection volume for SC administration in mice. ^[13]

For complete dosage calculation methodology including unit conversion, body-weight scaling, and concentration factor calculations, see our peptide dosage calculation guide.

Literature-Reported Research Doses

Published rodent studies have employed a wide range of dose levels depending on the experimental objective:

• Acute GH secretion studies: Single subcutaneous injections at 1-100 mcg/kg animal-equivalent in rats and mice are the predominant dose range in the literature. Lower doses in the 1-10 mcg/kg range produce modest GH pulses useful for studying dose-response relationships; higher doses in the 50-100 mcg/kg range typically produce near-maximal GH secretory responses in young rodents. ^[2]

• Chronic body composition studies: Alba et al. (2005) employed twice-daily subcutaneous injections over 4-12 week periods at doses up to 30 mcg/kg per injection in obese rodent models. ^[13]

• In-vitro receptor pharmacology: Concentrations ranging from 0.1 nM to 1 mcM are used for cAMP assays, receptor binding displacement assays, and downstream signaling characterization in pituitary cell lines. EC50 values for cAMP elevation in GHRHR-expressing cells are typically reported in the 0.5-2.0 nM range for Mod GRF(1-29) type analogues. ^[7]

Storage of Reconstituted Solution

Reconstituted CJC-1295 Without DAC is more susceptible to degradation than the lyophilized form. At 2-8°C, bacterial water-preserved solutions maintain acceptable purity for 4-6 weeks in most studies (the peptide's DPP-IV resistance limits one major degradation pathway, but oxidation and non-specific hydrolysis continue). For long-term storage of reconstituted solutions, single-use aliquots at -80°C are recommended. Avoid freeze-thaw cycling, which causes aggregation in many peptides of this molecular weight range.

Side Effects and Safety

Preclinical Safety Observations

In rodent studies employing chronic GHRH analogue administration, the most consistently reported adverse findings relate to the expected pharmacological consequences of sustained GH axis stimulation: organ hypertrophy (consistent with IGF-1-driven growth), insulin resistance at very high or continuous-exposure doses, and pituitary somatotroph hypertrophy with prolonged high-dose administration. ^[16]

Insulin resistance associated with GH-axis stimulation is mechanistically well understood: GH receptor activation in adipose tissue and liver promotes lipolysis and free fatty acid release, which competes with glucose oxidation and impairs insulin signaling via the diacylglycerol-PKC pathway. This effect is dose-dependent and is more pronounced with continuous GH elevation than with pulsatile patterns. Pulsatile GHRH-stimulated GH secretion (as produced by short-acting CJC-1295 Without DAC) generally shows less pronounced insulin resistance than equivalent GH AUC delivered as a continuous infusion, but researchers designing metabolic studies should include fasting glucose and insulin measurements as standard endpoints. ^[13]

Injection-Site Reactions

Local reactions at subcutaneous injection sites (redness, minor swelling, transient discomfort) are reported in animal studies and are consistent with the general experience of subcutaneous peptide administration. These reactions are typically mild and transient, resolving within 24-48 hours. They do not generally reflect systemic immunogenicity in short-duration studies. In longer-duration chronic-dose rodent protocols (>8 weeks), injection-site rotation is recommended in the research literature to prevent progressive local tissue changes. ^[15]

Immunogenicity Considerations

Peptide immunogenicity is a consideration for any non-native sequence in chronic dosing protocols. The four amino acid substitutions in Mod GRF(1-29) relative to native GHRH(1-29) theoretically could generate neo-epitopes not present in the endogenous sequence. Published studies on GHRH analogues have not reported clinically significant antibody formation against the peptide backbone in short-duration rodent studies (<12 weeks), but this has not been systematically evaluated in the context of CJC-1295 Without DAC specifically. ^[16] Researchers conducting multi-month studies should consider including anti-peptide antibody screening as a monitoring endpoint.

Interaction with Somatostatin Analogues

Researchers co-administering CJC-1295 Without DAC with somatostatin analogues (e.g., octreotide) in experimental designs intended to dissect the GH axis should be aware that somatostatin analogue pretreatment can essentially abolish the GH secretory response to GHRHR agonism. This is an expected pharmacodynamic interaction, not a toxicity, but it must be accounted for in study designs examining combinatorial peptide effects on the GH axis.

How It Compares

CJC-1295 Without DAC vs. CJC-1295 With DAC

The most important comparison for researchers selecting between these two compounds is the GH secretion pattern they produce. CJC-1295 Without DAC stimulates discrete GH pulses with a duration of 1-2 hours per injection, mimicking the physiological pulsatile secretion driven by endogenous hypothalamic GHRH. CJC-1295 With DAC, by contrast, produces a sustained, near-continuous GH elevation lasting days, which is pharmacologically analogous to exogenous GH infusion in its metabolic and tissue effects. ^[2]

If the research question involves pulsatile GH dynamics, somatotroph receptor desensitization, or the physiological GH-IGF-1 axis, CJC-1295 Without DAC is the appropriate tool. If the question involves chronic GH elevation, body composition over weeks without repeated injections, or modeling sustained GH exposure, CJC-1295 With DAC may be more tractable despite requiring longer washout periods between experiment arms.

CJC-1295 Without DAC vs. Ipamorelin (Combination Rationale)

Ipamorelin is a selective GHSR1a agonist that has become the most commonly paired GHRP in research protocols using CJC-1295 Without DAC. The combination rationale is mechanistically grounded: GHRHR (pituitary) and GHSR1a (pituitary plus hypothalamic suppression of somatostatin) stimulation via different receptor systems produces synergistic GH release that exceeds what either compound achieves alone. ^[10] Ipamorelin is favored over GHRP-2 or GHRP-6 in combination protocols because it has minimal off-target stimulation of cortisol, prolactin, and appetite hormones, allowing investigators to attribute non-GH outcomes to specific pathways rather than confounding adrenocortical or lactotroph activation.

Researchers designing combination studies should note that the GH response to the combination is not simply additive; it is supraadditive (synergistic) due to the dual mechanism of somatostatin suppression plus direct somatotroph activation. This means dose selection for combination protocols cannot be directly extrapolated from single-compound dose-response curves, and pilot experiments with GH time-course measurement are advisable.

CJC-1295 Without DAC vs. Tesamorelin

Tesamorelin is an FDA-approved GHRH analogue (for HIV-associated lipodystrophy) based on the full 44-residue GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus. It provides a useful benchmark for the regulatory and clinical evidence base in GHRH analogue research. CJC-1295 Without DAC differs in that it uses only the first 29 residues (with four stability-enhancing substitutions), making it more chemically tractable to synthesize at research scale, while Tesamorelin's full-length sequence provides a somewhat richer receptor contact surface. ^[17] For basic research purposes, either compound can activate GHRHR robustly; the choice is typically driven by cost, availability, and the specific research hypothesis.

Where to Buy

Apollo Peptide Sciences lists CJC-1295 Without DAC at $35.00 for a 5 mg vial. For a full evaluation of this listing, including lot-specific CoA data, vendor reputation, shipping considerations, and affiliate disclosure, see our CJC-1295 Without DAC product review page, which links directly to the Apollo Peptide Sciences listing.

For a broader comparison of peptide vendors, including quality tier assessments, CoA transparency ratings, and customer service benchmarks, see our research peptide supplier guide.

When evaluating any research peptide supplier, three non-negotiable criteria apply: (1) lot-specific CoA with both HPLC and MS data publicly available or provided on request; (2) third-party testing from an identifiable analytical laboratory, not just in-house QC claims; and (3) transparent disclosure of synthesis origin (domestic vs. overseas contract synthesis). Apollo Peptide Sciences provides CoA documentation meeting these criteria for the listed lot; researchers should request current lot documentation at the time of ordering, as lot numbers and associated QC data change with each synthesis batch.

For a more detailed breakdown of how to evaluate peptide vendor CoA documents, refer to our supplier selection guide.

Open Research Questions

The published literature on CJC-1295 Without DAC leaves several meaningful questions under-explored or contested.

Long-term receptor desensitization kinetics in aged models: Walker et al. (2012) documented attenuated GH responses in aged rodents but did not characterize GHRHR expression levels or receptor resensitization rates in the aged pituitary. Whether age-related GH axis decline reflects reduced GHRHR expression, altered G-protein coupling efficiency, or enhanced somatostatin tone remains unresolved for Mod GRF(1-29) specifically. ^[15]

Peripheral GHRHR effects independent of pituitary GH secretion: The low-level GHRHR expression in cardiac tissue, pancreatic islets, and immune cells raises the possibility of direct tissue effects not mediated through GH or IGF-1. Studies using hypophysectomized animal models to isolate peripheral GHRHR effects are sparse in the literature and have not been conducted specifically with the Mod GRF(1-29) sequence. ^[11]

Sex and gonadal hormone interactions: Estrogen modulates somatotroph GH secretory patterns, and many published GHRH analogue studies used exclusively male rodents. Whether CJC-1295 Without DAC produces equivalent GH responses in female animals, and how gonadectomy or estrogen supplementation modifies the response, is not well characterized. This is a practical gap because many preclinical disease models use female mice.

Optimal combination dosing ratios with GHRPs: Despite the widespread use of CJC-1295 Without DAC/Ipamorelin combinations in preclinical protocols, published data systematically characterizing the optimal molar ratio or timing offset between the two compounds is limited. A rigorous dose-matrix study examining GH AUC and pulse amplitude across a grid of CJC-1295 No DAC and Ipamorelin doses would substantially improve the evidence base for combination protocol design.

Pharmacological Context, GH Axis Biology and Pulsatile Secretion

Understanding why pulsatile GH secretion matters requires a brief overview of GH axis regulatory biology. The hypothalamic-pituitary GH axis operates as an ultradian oscillator: hypothalamic GHRH neurons fire in coordinated bursts, releasing GHRH into the portal capillaries that perfuse the anterior pituitary. Simultaneously, somatostatin neurons in the periventricular nucleus release somatostatin in an out-of-phase pattern, so that high somatostatin tone coincides with low GHRH secretion and vice versa. This push-pull arrangement produces GH pulses of approximately 45-90 minutes duration in rodents and 3-4 hours in humans. ^[9]

The amplitude and frequency of GH pulses, rather than mean GH levels, govern downstream biological outcomes in a tissue-specific way. Liver transcription factor activation, IGF-1 synthesis, and sexual dimorphism in hepatic gene expression are all pulse-pattern-dependent rather than mean-GH-dependent. Sex differences in GH pulse pattern (males have higher-amplitude, lower-frequency pulses; females have lower-amplitude, higher-frequency pulses) drive major differences in hepatic gene expression and metabolic phenotype, even when mean 24-hour GH exposure is similar. ^[9]

This biological background explains why the short-acting GHRH analogue (CJC-1295 Without DAC) is preferable to the long-acting DAC version for most mechanistic GH axis research: continuous GH stimulation produced by the DAC version disrupts the pulsatile pattern and results in a GH secretory phenotype that does not exist in normal physiology. Researchers studying GH-pulse-dependent processes (e.g., STAT5b-regulated hepatic gene expression, sexual dimorphism in IGF-1 binding proteins) will obtain more physiologically interpretable data from pulsatile-pattern stimulation. ^[18]

Ghrelin, produced by gastric X/A-like cells, adds a third input to the hypothalamic-pituitary-GH axis: it amplifies GHRH-stimulated GH release and suppresses somatostatin release simultaneously, functioning as a permissive signal that scales GH pulse amplitude to nutritional status. This is why GHRP-based compounds produce synergistic effects when combined with GHRHR agonists: they engage the ghrelin receptor pathway that amplifies the GHRH signal through a parallel and partially independent mechanism.

FAQ